Local structural elements in the mostly unstructured transcriptional activation domain of human p53 H Lee, KH Mok, R Muhandiram, KH Park, JE Suk, DH Kim, J Chang, ... Journal of Biological Chemistry 275 (38), 29426-29432, 2000 | 385 | 2000 |
A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease SS Hayek, KH Koh, ME Grams, C Wei, YA Ko, J Li, B Samelko, H Lee, ... Nature medicine 23 (8), 945-953, 2017 | 204 | 2017 |
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2 N Drayman, JK DeMarco, KA Jones, SA Azizi, HM Froggatt, K Tan, ... Science 373 (6557), 931-936, 2021 | 190 | 2021 |
MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling JS Yi, JS Park, YM Ham, N Nguyen, NR Lee, J Hong, BW Kim, H Lee, ... Nature communications 4 (1), 2354, 2013 | 173 | 2013 |
Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein− ligand X-ray structure and biological evaluation AK Ghosh, J Takayama, KV Rao, K Ratia, R Chaudhuri, DC Mulhearn, ... Journal of medicinal chemistry 53 (13), 4968-4979, 2010 | 168 | 2010 |
Structure and function of the phosphothreonine-specific FHA domain A Mahajan, C Yuan, H Lee, ESW Chen, PY Wu, MD Tsai Science signaling 1 (51), re12-re12, 2008 | 159 | 2008 |
Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus H Lee, J Ren, S Nocadello, AJ Rice, I Ojeda, S Light, G Minasov, J Vargas, ... Antiviral research 139, 49-58, 2017 | 138 | 2017 |
Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV H Lee, H Lei, BD Santarsiero, JL Gatuz, S Cao, AJ Rice, K Patel, ... ACS chemical biology 10 (6), 1456-1465, 2015 | 135 | 2015 |
Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity Z Shen, K Ratia, L Cooper, D Kong, H Lee, Y Kwon, Y Li, S Alqarni, ... Journal of medicinal chemistry 65 (4), 2940-2955, 2021 | 129 | 2021 |
Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators AD Jain, H Potteti, BG Richardson, L Kingsley, JP Luciano, AF Ryuzoji, ... European journal of medicinal chemistry 103, 252-268, 2015 | 97 | 2015 |
Rufomycin targets ClpC1 proteolysis in Mycobacterium tuberculosis and M. abscessus MP Choules, NM Wolf, H Lee, JR Anderson, EM Grzelak, Y Wang, R Ma, ... Antimicrobial agents and chemotherapy 63 (3), 10.1128/aac. 02204-18, 2019 | 93 | 2019 |
Diphosphothreonine-specific interaction between an SQ/TQ cluster and an FHA domain in the Rad53-Dun1 kinase cascade H Lee, C Yuan, A Hammet, A Mahajan, ESW Chen, MR Wu, MI Su, ... Molecular cell 30 (6), 767-778, 2008 | 90 | 2008 |
Airway epithelial cell-derived colony stimulating factor-1 promotes allergen sensitization HG Moon, S Kim, JJ Jeong, SS Han, NN Jarjour, H Lee, ... Immunity 49 (2), 275-287. e5, 2018 | 67 | 2018 |
Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings H Lee, A Mittal, K Patel, JL Gatuz, L Truong, J Torres, DC Mulhearn, ... Bioorganic & medicinal chemistry 22 (1), 167-177, 2014 | 67 | 2014 |
Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro R Du, L Cooper, Z Chen, H Lee, L Rong, Q Cui Antiviral research 190, 105075, 2021 | 60 | 2021 |
Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases Z Chen, Q Cui, L Cooper, P Zhang, H Lee, Z Chen, Y Wang, X Liu, L Rong, ... Cell & Bioscience 11, 1-8, 2021 | 58 | 2021 |
Targeting SARS‐CoV‐2 viral proteases as a therapeutic strategy to treat COVID‐19 V Anirudhan, H Lee, H Cheng, L Cooper, L Rong Journal of medical virology 93 (5), 2722-2734, 2021 | 51 | 2021 |
High-resolution structure of ClpC1-rufomycin and ligand binding studies provide a framework to design and optimize anti-tuberculosis leads NM Wolf, H Lee, MP Choules, GF Pauli, R Phansalkar, JR Anderson, ... ACS infectious diseases 5 (6), 829-840, 2019 | 51 | 2019 |
Reducing agents affect inhibitory activities of compounds: results from multiple drug targets H Lee, J Torres, L Truong, R Chaudhuri, A Mittal, ME Johnson Analytical biochemistry 423 (1), 46-53, 2012 | 47 | 2012 |
Hit-to-Lead: hit validation and assessment KE Hevener, R Pesavento, JH Ren, H Lee, K Ratia, ME Johnson Methods in Enzymology 610, 265-309, 2018 | 43 | 2018 |